Ignite Creation Date:
2024-05-06 @ 8:13 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06304844
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-18
First Post:
2024-03-05
Brief Title:
Risk of CKD in Diabetic Patients With MAFLD
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Assessing the Risk of Chronic Kidney Disease Associated With Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease CKD in individuals with metabolic dysfunction-associated fatty liver disease MAFLD and type 2 diabetes By evaluating hepatic measurements and metabolic markers the study aims to identify key risk factors for CKD in this population contributing valuable insights to inform targeted interventions
Detailed Description:
investigators plan to enroll 300 participants with type 2 DM to comprehensively investigate the risk of chronic kidney disease CKD in individuals diagnosed with metabolic dysfunction-associated fatty liver disease MAFLD and type 2 diabetes mellitus
In this study the participant population will be grouped based on presence of MAFLD or not into 2 groups then the group with MAFLD will be subdivided into subgroups based on the degree of hepatic involvement considering both controlled attenuation parameter CAP values for steatosis and liver stiffness measurements for fibrosis via fibro scan device This grouping strategy aims to categorize individuals into distinct cohorts such as Low Hepatic Involvement and High Hepatic Involvement groups facilitating a nuanced exploration of the association between hepatic conditions and the risk of chronic kidney disease CKD in the context of metabolic dysfunction-associated fatty liver disease MAFLD and type 2 diabetes mellitus
In this study the participant population will be grouped based on presence of MAFLD or not into 2 groups then the group with MAFLD will be subdivided into subgroups based on the degree of hepatic involvement considering both controlled attenuation parameter CAP values for steatosis and liver stiffness measurements for fibrosis via fibro scan device This grouping strategy aims to categorize individuals into distinct cohorts such as Low Hepatic Involvement and High Hepatic Involvement groups facilitating a nuanced exploration of the association between hepatic conditions and the risk of chronic kidney disease CKD in the context of metabolic dysfunction-associated fatty liver disease MAFLD and type 2 diabetes mellitus
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None